Meet the Greek: Dr. Rachael Safyan, a researcher focused on pancreatic, colorectal cancer

In this episode of Oncology Insights, Dr. Petros Grivas and Dr. Rachael Safyan discuss the advancements in gastrointestinal oncology, focusing on pancreatic cancer research, the importance of clinical trials, and the collaborative efforts between Fred Hutch and community oncologists. Dr. Safyan shares her journey, her role as the research director, and the multidisciplinary approach taken to enhance patient care. The conversation highlights the significance of germline testing and the future vision for GI oncology, emphasizing the need for increased clinical trials and community engagement. Takeaways Dr. Rachael Safyan is the new research director for GI Medical Oncology. The GI oncology program at Fred Hutch is robust with 11 faculty members. Collaboration with community oncologists is essential for patient access to trials. A multidisciplinary approach is crucial for comprehensive patient care. Germline testing is recommended for all pancreatic cancer patients. The program focuses on various GI cancers including pancreatic and biliary tract cancers. Clinical trials are becoming more biomarker-selected and patient-centered. Community engagement is key to improving patient outcomes. The future vision includes expanding clinical trials to community sites. Patient care should prioritize both physical and mental well-being.